Mathematical Models in Drug Dosage and Administration

Sidra Altaf[1,*], Nadia Idrees[2], Saeed Akhtar[3], Rabia Munir[2] and Muhammad Saleem[4]

[1]Department of Pharmacy, University of Agriculture, Faisalabad, Pakistan
[2]Department of Mathematics and Statistics, University of Agriculture, Faisalabad, Pakistan
[3]Nayab Fertility Clinic Faisalabad, Pakistan
[4]Institute of Physiology and Pharmacology, University of Agriculture Faisalabad, Pakistan
*Corresponding author: sidra.altaf@uaf.edu.pk

Abstract

Mathematical models are instrumental in drug regimen optimization related to dosage and administration, optimizing available therapy while potentially reducing unwanted effects. The chapter emphasizes principles of pharmacokinetics and pharmacodynamics in the context of mathematical models that are useful to predict drug behavior in humans. First, the models will facilitate the forecasting of how drugs are absorbed, distributed, metabolized, and excreted, using compartment models and physiological-based pharmacokinetic (PBPK) models outlined in the first half of the chapter. Furthermore, pharmacodynamic models explain how the concentration of the drug correlates to the potential therapeutic effect. This includes aspects of both time-dependent responses and nonlinear kinetics in both models. Some applications of these models to clinical practice are introduced, including an example of therapeutic drug monitoring (TDM), and the use of pharmacokinetic and pharmacodynamic models for personalized medicine. This highlights that while patients may be prescribed the same medication, differences may occur from how a person absorbs, distributes, metabolizes, or excretes a medication, thus creating a potential for individualized drug regimens. There are challenges of model accuracy, including simplifying a tremendous biological system and the amount of information that must be incorporated. More recently, the methods of computational power, mathematic and other data sources and media have enabled models to become more accurate (p. 270). There is also a look to the future on the implications of machine learning and artificial intelligence to pharmacokinetics models. The chapter reinforces the link between theory and practice in this area, and how mathematical models have the potential to improve drug development, clinical decisions, and ultimately patient outcomes.

Keywords: Pharmacokinetics, Pharmacodynamics, Drug Dosage, Mathematical Modeling, Therapeutic Drug Monitoring, Personalized Medicine.

Cite this Article as: Altaf S, Idrees N, Akhtar S, Munir R and Saleem M, 2025. Mathematical models in drug dosage and administration. In: Farooqi SH, Kholik K and Zaman MA (eds), One Health Horizons: Integrating Biodiversity, Biosecurity, and Sustainable Practices. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 196-203. https://doi.org/10.47278/book.HH/2025.434

A Publication of Unique Scientific Publishers

Chapter No: 25-027

Received: 19-Jan-2025
Revised: 31-Apr-2025
Accepted: 04-May-2025

Introduction

Drug doses and administration are important components of pharmacology and clinical practice as both worry about the correct amount of drug given to a patient in the correct circumstances so that patients have the desired medical effects from their drug with minimal ability to adverse reactions. Dosage and administration also need to consider the patient's age, weight, comorid health conditions and individual pharmacodynamics properties of the drug (Saleem et al., 2024).

This balance is particularly important for drugs with narrow therapeutic indices, where small changes in the dose can result in adequate results. In addition to these factors, the patient's adherence, genetic differences and Comorbidities can add additional challenges; Thus, adaptation of drug therapy requires a holistic and personal approach (Bicker et al., 2020).

Mathematical models have become important tools in pharmacology, providing a quantitative approach to understand, predict and optimize drug functions in the body. Mathematical models integrate ideas from mathematics, biology and chemistry for drug functions and assistance decisions in the clinic. The concepts of using mathematical models in pharmacology began with the presentation of pharmacocyanate models describing drug absorption, distribution, metabolism and emission (ADME) in the early 20th century. Some of the first pioneers were selected to use and detect compartmental modeling of drug activities, Vermark and Tendberg. Compartmental modeling is still the fundamental method of pharmacocinetics. Since these early models, the increase in computational capabilities and the availability of data has created more complex models, such as physically based pharmacocyannetic (PBPK) model and pharmacodynamic (PD) model (Saleem et al., 2024).

2. Basic Pharmacokinetic Principles

Pharmacokinetics (PK) is the study of what happens to a drug in the body and includes all aspects of: absorption, distribution, metabolism, and excretion (ADME). Comprehending these principles is necessary to design a proper dose regimen and predict the behavior of the drug in the body (M. U. Iqbal et al., 2024).

Absorption, Distribution, Metabolism, and Excretion (ADME)

ADME describes the four key processes that determine the fate of a drug in the body.

Absorption

Absorption refers to the route that a drug takes from the site of administration (oral, I.V., topical, etc.) to the bloodstream and is important because it determines how quickly and how well a drug will exert its therapeutic effect. Absorption occurs by several mechanisms. Passive diffusion is what occurs most often: for example, it is the process by which drugs move from an area of higher concentration to one of lower concentration; no energy is used. Active transport, in contrast, involves using energy (ATP) and carrier proteins to move a drug from an area of lower concentration to one of higher concentration. This method of absorption is utilized with drugs that mimic substances present in the body. Facilitated diffusion is similar to passive diffusion but allows a drug to use carrier proteins to assist the drug in moving down a concentration gradient. Both of these processes include factors that may affect absorption. For example, drug characteristics like solubility, molecular size, and charge, etc. may impact absorption rates (Umair et al., 2022).

Distribution

Distribution is the transport of a drug from the vascular compartment into tissues and organs of the body. After drug absorption, the drug is introduced to the vascular system where is transported everywhere in the body that drug effect can occur. Several processes are involved in distribution including transport through the blood, pharmacologic effect, binding to plasma proteins like albumin, and distribution to tissues or organs. Factors affecting distribution include organ blood flow (organs with the highest blood flow such as lungs, liver, and kidneys will receive the drug first), lipophilicity (the ability to cross membranes), and active transport systems. Lipophilicity is the degree of solubility of a drug in lipids. The more lipid soluble, the more likely the drug can enter the tissues. Distribution accounts for the amount of a drug that is either bound or unbound. The amount of drug that is bound to plasma proteins does affect the distribution of a protein, but only free, or unbound, drug is active and capable of reaching the target tissue (Ali et al., 2024).

Metabolism

Metabolism is the process of chemically modifying a drug (mostly in the liver) to increase its water solubility and facilitate elimination from the body. Metabolism is a critical part of conversion of drugs to convert them into easily eliminated forms. Digesting metabolism has Phase-I reactions - oxidation, reduction and hydrolysis which are done by cytochrome P450 enzymes. Phase-I reactions usually only have functional groups added to the drug which is introduced or exposed (T. Iqbal, Altaf, Salma, et al., 2024).

Phase II reactions involve conjugation, where a drug or Phase I metabolites are conjugated with glucuronic acid, sulfate or glutathione, and further increase the polarity or water solubility of the drug. Variability in metabolism can be impacted by several factors, including genetic variability affecting enzyme activity, for example, polymorphisms in CYP450 metabolism which can result in differences in the metabolism of drugs between individuals. Liver function must also be taken into account, as disease or impairment can have major effects on capacity for metabolism (T. Iqbal & Altaf, 2024).

Excretion

Excretion is the process of eliminating a drug and its metabolites from the body mostly through the kidneys (urine) and the liver (bile). An important part of the excretion process is renal excretion, which is made up of filtration, secretion, and reabsorption for losing a drug, as well as biliary excretion which includes elimination through feces. Factors that may influence excretion includes kidney function (glomular filtration rate), drug properties (molecular weight and polarity) and urine pH, which can influence the reabsorption of weak acids and bases (Altaf et al., 2024).

Pharmacokinetic Parameters

Pharmacokinetic parameters provide a framework for quantifying the ADME processes and describing or predicting the behavior of drugs in the body. The important pharmacokinetic parameters include clearance (CL), which is the volume of plasma from which a drug is completely removed in a unit of time (e.g., mL/min or L/h). CL is a measure of the efficacy of the clearance process by existing organs (e.g., liver, kidneys or other organs). The volume of distribution (Vd) is a theoretical volume needed for drug to be uniformly distributed to achieve the plasma concentration in observation. Vd is an indication of how widely drug distributes throughout the body. A high Vd indicates considerable distribution to tissues, while a low Vd means distribution is especially confined to the plasma compartment (T. Iqbal, Altaf, Fatima, et al., 2024).

Half-life ($t_{1/2}$) refers to the time it takes for the plasma concentration of a drug to decrease by half, and it helps establish dosing interval and time to steady-state concentrations. Bioavailability (F) refers to the fraction of an administered dose (F_1) which reaches the systemic circulation (F_a), that is unchanged (F_2). Bioavailability encompasses the absorption efficiency and the first-pass metabolism a drug undergoes. The bioavailability for intravenous administration is 100% because the drug does not undergo anything that affects its concentration, however for oral administration, its bioavailability will be less than 100% due to either incomplete absorption, or first-pass metabolism. The four processes ADME and pharmacokinetic parameters give reference frame on how drugs move around the body and their change in concentration over time (T. Iqbal, Altaf, Basit, et al., 2024).

3. Types of Mathematical Models in Drug Dosage

Pharmacology relies heavily on mathematical models to predict drug behaviour, develop dosing regimens, and analyze possible mechanisms of drug action. Models are generally classified into three types: compartmental models, non-compartmental models, and physiologically-based pharmacokinetic (PBPK) models. Each class of model has its own characteristics, advantages, and potential uses (T. Iqbal, Salma, et al., 2024).

Compartmental Models

Compartmental models identify the body as one or more compartments, or theoretical compartments that show how drugs are distributed and processed. Compartmental models are used often given their simplicity and ability to mathematically describe drug kinetics. The one-compartment model suggests that the body is a homologous compartment and the drug distributes evenly. It is simple model and it lends easily to describing the concentration over time of a drug as a function of exponential equations. It can be used with drugs that rapidly distribute throughout the body when administered method acetaminophen (intravenous bolus) and is typically used in the earliest pharmacokinetic studies (Foster & Vicini, 2022). Multi-compartment models are used to separate the body into two compartments, and often more than that, through the use of central and peripheral compartments. These models allow for an accurate analysis of drug distribution and elimination by acknowledging the various tissue types present in the body. The central compartment is representative of the body components, such as blood, liver, and kidney, containing highly perfused organs, while the peripheral compartment is representative of poorly perfused tissues such as adipose tissue and muscle. These models can be rapidly complicated with the introduction of additional coaches, but they provide better representation of drug disposal than the two-dibbe models. These types of models describe drug behavior related to non-lectural distribution (ie, lipophilic drugs) and are regularly employed in more sophisticated pharmacocyanic studies and drug development (Altaf & Iqbal, 2023).

Non-Compartmental Models

Non-Complemental Analysis (NCA) is a data-powered approach that analyzes the data on the drug concentration versus time without the need for a specific compartment approach. They are simple, flexible, and require less beliefs than compartmental models. Clinical trial may be suitable for using NCA models, for data and to estimate parameters such as the curve (AUC), clearance and fields under half-life. They have limited mechanical value and are not reliable to introduce concentrations outside the phenomenon of data. NCA is often used in bio - synchronizing study and in phase I clinical trials (T. Iqbal et al., 2023).

Physiologically-Based Pharmacokinetic (PBPK) Models

PBPK models are sophisticated, mechanical tools that describe drug behavior using compartments in the body with physical and physical information, such as, liver, kidneys, which share blood flow. These models include physical parameters, unique properties of drug and population such as child diseases or pharmacocinetics in pregnant women, and are also used to simulate drug-drug interactions. Although they are highly forecasted and imitating variability, PBPK models are data and computationally intensive (Fatima et al., 2023).

4. Modeling Drug Absorption

Drug absorption describes the rate of transfer of a drug from its site of administration into systemic circulation. It is an important factor within pharmacokinetics. Mathematical models can describe the process of drug absorption, and each model choice should take into account the mechanisms of response and the properties of the drug (Humaira et al., 2023).

First-Order Kinetics

First-order kinetics describes drug absorption by a drug where the drug absorption rate is either the first derivative of the remaining drug at the site of absorption and thus also proportional to it. The expression is dAdt=−kaAdtdA = −kaA, with A(t)=Aoe−katA(t)=Aoe−kat which tells you the amount at any time in the past (Wadhwa & Cascella, 2020).

Zero-Order Kinetics

Zero-order kinetics is when how well your body can absorb drug into the bloodstream is constant regardless of drug concentration, generally expressed via mathematical equations dAdt=−kodtdA=−ko and A(t)=Ao−kotA(t)=Ao−ko, which details the total amount of drug that the body has absorbed/taken over time t. Zero-order absorption applies to controlled release formulations as well as intravenous infusions, where the body has a constant dosage/drug concentration in the bloodstream. These calculations can help to build steady-state or sustained-release systems and estimate steady-state concentrations of drug in the bloodstream (Askarizadeh et al., 2023).

Michaelis-Menten Kinetics

Michaelis-Menten kinetics describes drug absorption involving saturable processes. At low concentrations the rate will increase linearly (first-order) and once saturation occurs then the rate becomes independent of drug concentration (zero-order). The rate of absorption is expressed as dAdt=Vmax·AKm+AdtdA=Km+AVmax·A, where VmaxVmax is the maximum rate of absorption, KmKm is the Michaelis constant and AA is the amount of drug. The theory of Michaelis-Menten kinetics is important for modeling nonlinear pharmacokinetics, dosing optimization and predicting drug-drug interactions as a result of carrier-mediated transport or enzyme-catalyzed metabolism (Peters, 2021).

5. Modeling Drug Distribution

The drug distribution is the instrument by which the drugs run from the bloodstream to tissues and organs. Mathematical models are used to describe and predict the drug distribution. Drug distribution includes blood flow, drug permeability and features of the drug. Major concepts will include the volume of distribution and tissue distribution models (Wu et al., 2023).

Volume of Distribution

The volume (VD) is a theoretical remedy that indicates the location in the body occupied by a drug. VD is calculated as VD = ACPVD = CPA, where AA is the total amount of the drug, and CPCP is plasma concentration. A VD who is high, indicates adequate drug distribution in tissues (eg, lipophilic drugs), while a low VD indicates distribution to blood (eg, protein-bound drugs). Factors affecting VD include lipophylicity, molecular shape, protein binding, blood flow, tissue permeability and body structure, making it an important solution in pharmacokinetics (Contri et al., 2022).

Table 1: Overview of various mathematical models used in drug dosage and administration

Sr.No	Model Type	Application	Key Features	Advantages	Limitations	Examples	References
1	Pharmacokinetic (PK)	Drug absorption, distribution, metabolism, excretion (ADME)	Describes drug concentration over time using differential equations	Predicts drug levels, optimizes dosing	Assumes homogeneity; ignores individual variability	Vancomycin TDM, Warfarin dosing	(Emmett et al., 2019)
2	Pharmacodynamic (PD)	Drug effect on the body	Links drug concentration to therapeutic or toxic effects	Predicts efficacy and toxicity	Complex biological systems may not be fully captured	Antibiotic efficacy models	(Preijers et al., 2024)
3	PK/PD Combined	Dose optimization	Integrates PK and PD to predict drug response	Provides comprehensive dosing strategies	Requires extensive data for calibration	Oncology drug dosing	(Papachristos et al., 2023)
4	Compartmental	Drug distribution in the body	Divides the body into compartments (e.g., blood, tissues)	Simplifies complex systems	May oversimplify biological processes	Two-compartment model for IV drugs	(Heramvand, 2023)
5	Non-Compartmental	Drug exposure analysis	Analyzes drug concentration-time curves without compartments	Easy to apply; useful for early-phase studies	Limited mechanistic insights	Bioavailability studies	(Mittal et al., 2023)
6	Population PK/PD	Variability in drug response	Accounts for inter-individual variability in drug handling and effects	Tailors dosing for diverse populations	Requires large datasets	Pediatric dosing models	(Xiao, 2022)
7	Mechanistic	Biological system simulation	Models biological processes at molecular, cellular, or organ levels	High predictive accuracy for complex systems	Computationally intensive; requires detailed data	Cancer growth and treatment models	(Sharif et al., 2025)
8	Empirical	Data-driven predictions	Uses statistical methods to fit observed data	Simple and fast	Limited extrapolation beyond observed data	Dose-response curves	(Vlot et al., 2019)
9	Stochastic	Variability and uncertainty	Incorporates randomness in drug behavior	Accounts for biological variability	Computationally demanding	Monte Carlo simulations for drug trials	(Wang et al., 2020)
10	Physiologically-Based PK (PBPK)	Drug behavior in specific organs	Simulates drug ADME based on physiological parameters	Predicts organ-specific drug effects	Requires detailed physiological data	Liver or kidney impairment models	(Ramadan et al., 2021)
11	Bayesian	Adaptive dosing	Updates model predictions using prior knowledge and new data	Enables real-time dose adjustments	Dependent on quality of prior data	TDM for aminoglycosides	(Onita et al., 2025)
12	Machine Learning (ML)	Predictive analytics	Uses algorithms to identify patterns in large datasets	Handles complex, high-dimensional data	Black-box nature; requires large datasets	Predicting drug-drug interactions	(Terranova et al., 2024)
13	Digital Twin	Personalized medicine	Creates virtual replicas of patients for simulation	Enables individualized treatment optimization	Requires extensive patient-specific data	Oncology treatment planning	(Zhao et al., 2024)
14	Multi-Scale	Integration of biological levels	Combines molecular, cellular, and organ-level models	Captures complex interactions	High computational cost	Drug development for chronic diseases	(Barros et al., 2024)
15	Hybrid	Combines mechanistic and data-driven approaches	Integrates mechanistic models with ML/AI for enhanced predictions	Balances accuracy and interpretability	Complex to develop and validate	Adaptive clinical trial designs	(Jebreili & Goli, 2024)

Tissue Distribution Models

Sprayed and proliferation-limiting models are classified based on tissues, and retailimiting steps. The sprayed model features a rapid balance between blood and tissue. In spray-limit distribution, distribution is dependent on blood flow (dctdt = qt/kp) dtdct = qt (cp k ct/kp)), and applies to highly percured tissues like liver and kidney. Diffusion-limited models stipulate that the rate-limiting step will be slow membrane permeation, distribution will be dependent on permeability and surface area (dCtdt=PS(Cp−Ct)dtdCt=PS(Cp−Ct)), and applies to areas of the

body such as the brain or poorly perfused tissues. This knowledge is useful for predicting drug behavior to optimize dosing, and can help to understand distribution into various tissues and in different populations (Altaf, Iqbal, et al., 2023). Overview of various mathematical models used in drug dosage and administration has been elaborated in Table 1.

6. Modeling Drug Metabolism and Elimination

Drug metabolism and elimination determine how long a drug and its effects will endure within the body. Mathematical models describing drug metabolism and elimination occur in liver (metabolism) and kidneys (elimination). The use of these models is essential to the behavior of drugs after administration, and to establish optimal dosing regimens (Gharat et al., 2024).

Hepatic Metabolism

In the liver, the first step in the metabolism of drugs is by the use of enzymes such as cytochrome P450 (CYP) in Phase I reactions, and Phase II enzymes through conjugation involving both endogenous substrates and drugs, to improve water solubility for renal and other excretion. Models of hepatic clearance such as well-stirred and parallel-tube models estimate drug elimination based on hepatic blood flow, enzyme activity responsible primarily for Phase I, and drug binding. Indices for factors, such as genetic polymorphisms, drug interactions, and liver health respectively, can considerably affect their metabolic efficiency (Saqib et al., 2023).

Renal Elimination

Kidney excretion of drugs and metabolites occurs via glomerular filtration, tubular secretion, and reabsorption. Glomerular filtration rate (GFR) indicates blood filtration capability (filtration ~90–120 mL/min in adult healthy subjects), and significantly impacts drug excretion rates. Renal clearance (CLR) indicates the volume of plasma that clears drugs. CLR is influenced by GFR, tubular secretion (penicillin), and reabsorption (water-soluble drugs) (Veiga-Matos et al., 2020).

Nonlinear Pharmacokinetics

Nonlinear pharmacokinetics occurs when the metabolic or elimination pathway for a drug becomes saturated, resulting in disproportionate changes in concentration for a given change in dosage. Such saturation may be caused by saturation of enzymes or saturable transporters, which may give rise to zero-order kinetics such as phenytoin, whose narrow therapeutic index makes it essential to be careful with dosing (Altaf, Khan, et al., 2023).

7. Pharmacodynamic Models

Pharmacodynamics (PD) examines the concentration of a drug and its medicinal effects. Pharmacodynamic models help to explain how the effects of the drug change with concentration and time, and help identify the efficacy and safety of the drug, and to determine the optimal dosage. These models are important when evaluating therapeutic and toxic effects of the drug (F. Saleem et al., 2023).

Relationship between Drug Concentration and Effect

The relationship between the concentration and its effect of a drug is often described mathematically using an Emax model, which contains a hyperbolic curve, where the effect eventually grows as concentrations as a plateau and is also described using a sigmoid emax model, which provides a cigomelle size to depicce the possibility of stapper or more complex relationships. The Emax model is mathematically defined: E = Emax) CEC50 + CE = EC50 + Emax · C, and Sigmoid Emax includes a mountain coefficient (NN) to provide more flexibility, as follows: E = emax·cnnec50n + cnemx These models have been used extensively to estimate drug potency and efficacy and to provide drug binding characteristics in pregnant and clinical studies (Mushtaq et al., 2024).

Time-Dependent Pharmacodynamics

In some conditions, the effects of drugs demonstrate delays as changes in concentrations, causing timely pharmacodynamics. It is displayed through the hysteris loops that indicate the delay in time occurring due to slow distribution, other indirect mechanisms, or tolerance between potential other factors. Effect compartment and indirect response models can describe this type of delayed drug actions in a consistent manner. These models are important when optimizing dosage regimens to determine the time limit for potential therapeutic effects (Lamba & Pesaresi, 2022).

8. Optimization of Drug Dosage Regimens

In order to achieve therapeutic objectives and reduce toxicity, it is imperative to optimize drug dosing regimens by adjusting drug doses based on patient characteristics, enhancing our understanding of variability in drug response, and applying modeling approaches to model and adapt drug dosing. The common approaches include the target concentration strategy, individualized dosing, and population pharmacokinetics (Altaf & Iqbal, 2024).

Target Concentration Strategy

The target concentration strategy establishes drug concentration in order to reach a level of efficacy that is balanced by safety, allowing drug dosages to be adjusted accordingly. Factors that could affect the appropriate dose decisions include as a therapeutic index, physician or illness, organ function. Therapeutic drug monitoring helps establish an effective drug concentration level that is optimal for the treatment (Salma et al., 2023).

Individualized Dosing

Patient-centered dosing promotes drug therapy optimizing individual characteristics, such as genetic factors and biomarkers. Pharmacogenomics will assist in determining an individual's drug metabolism, thereby increasing efficacy and safety. Biomarkers including, but not limited to, HbA1c or troponin will help determine the dosage and adjustments with the ultimate goal of improving treatment outcomes. The benefits to pharmacogenomic and biomarker-dosed therapies is an advancement in precision medicine; ultimately reducing adverse effects and increasing patient care (Gulnaz et al., 2023).

Population Pharmacokinetics

Population pharmacokinetics (PopPK) is the application of statistical models to account for variability in drug responses and allow dose optimization for diverse patient populations. This variability can stem from differences in age, genetic differences and diseases. Each patient has characteristics that influence drug disposition and response to treatment. Bayesian methods combine individual patient pharmacokinetic data with population PK models to adjust doses for individuals (Meesters et al., 2024). This method improves drug efficacy and safety, especially in special populations. Each of these strategies and methods are critical to optimizing the patient's drug therapy so the drug obtains the intended effect while preventing these adverse (toxic) effects. As we see improvements in pharmacogenomics, biomarkers, and Bayesian modeling, we are moving toward a personalized medicine model where treatments will not only be increasingly individualized but also matched to a patient's drug therapy needs (Sharma et al., 2022).

9. Applications of Mathematical Models in Clinical Practice

Mathematical models are a valuable tool in contemporary clinical settings, especially in the field of Therapeutic Drug Monitoring (TDM), Drug Development, and Personalized Medicine. In TDM, pharmacokinetic (PK) and pharmacodynamic (PD) models are sometimes used to predict drug concentrations and effects. This approach permits personalized dosing, and minimizes toxicity. These are most often applied in real-time scenarios, such as where clinicians optimize vancomycin dosing in the setting of infection, or ensure that anticoagulant therapy (e.g. Warfarin) reaches a target therapeutic INR. In the case of drug development, predictive modeling can link preclinical and clinical studies, when making decisions about safe starting doses and providing information on adaptive trial design (Saleem et al., 2024).

Regulatory bodies such as the FDA advocate for the use of Model-Informed Drug Development (MIDD) informing drug approvals and establishing exposure-response relationships. In personalized medicine, models use genetic and clinical data to predict patient response and facilitate precision dosing and individualized treatment plan development. In future, additional technology, such as AI, machine learning, digital twins, wearable devices, and multi-omics will improve model precision and facilitate decision making in real time. Although there are challenges for the advancement of mathematical modelling including biases in the data, quality of data available, deconvoluting the signal and noise and complexity of the biological systems, mathematical models will be critical for as if every patient is individual as such models strive to create a more equalized state for personalized treatment to be implemented and facilitate speeding drug development. As a way to improve therapeutic outcomes across a wide range of clinical settings and minimize harm, mathematical models will be critical to personalizing treatment and optimizing drug development (T. Iqbal et al., 2024).

10. Challenges and Future Directions

Although mathematical models have made incredible contributions to clinical practice, we must learn from the limitations of the models (like simple assumptions, data gaps, and ethical problems). The availability of computational power, and data, as well as the exciting prospects offered by AI, provide a unique opportunity to accelerate innovations, while at the same time counterbalancing the complexities that remain. With a balance of innovation and regulation, as well as a deeply rooted sense of ethical consideration, it is conceivable that mathematical models will be integral to improving patients' lives, and focusing on their care, even in transformative health care systems (Faisal et al., 2024).

Conclusion

Mathematical models have already become essential components in optimizing drug dose and administration schemes, improving treatment efficacy, and reducing side effects. Mathematical models integrate pharmacokinetic and pharmacodynamic properties, allowing for individualized therapy based on patient factors. Emerging computational capabilities, big data, and AI will change the landscape of the field again, allowing for more accurate, real-time, and increasingly complex simulations. Opportunities abound for precision medicine, streamlining the drug development, and utilizing dynamic dosing paradigms as information emerges with continuous monitoring. Key challenges remain with validation, ethical and privacy considerations, and research has to ensure the safe, fair, and ethical use of these models going forward. With any new technology, Mathematical models will continue to investigate new frontiers, influence the practice of pharmacology/medicine, drive innovation, improve outcomes, and make the health care system more predictive, preventive, and personalized.

References

Ali, A., Husnain, R., Bakht, M. B., & Tasawar, I. (2024). The Effects on Climate Change Due to Kitchen Waste Composting and Emissions of Carbon Dioxide. *Nangarhar University International Journal of Biosciences*, 193–196.

Altaf, S., & Iqbal, T. (n.d.). *Poly Lactic-co-Glycolic Acid Nanoparticles for Drug Delivery*.

Altaf, S., & Iqbal, T. (2023). Bee Venom Used for the Treatment of Rheumatoid Arthritis. *Biomedical Journal of Scientific & Technical Research*, *53*(2), 44503–44507.

Altaf, S., Iqbal, T., Majeed, W., Farooq, M. A., Naseer, D., Saleem, M., Babar, S. U. R., & Ikram, M. (2023). Plasma membrane camouflaged nanoparticles: an emerging antibacterial approach. *One Health Triad, Unique Scientific Publishers, Faisalabad, Pakistan*, *2*, 193–200.

Altaf, S., Iqbal, T., Salma, U., Sajid, M., Basit, I., Sabir, M. Z., Riaz, K., Rasheed, R., Umair, M., & Talha, R. (2024). *Gold nanoparticles for the*

detection of organophosphate. Agrobiological Records 16: 11-18.

Altaf, S., Khan, S., Iqbal, T., Farooq, M. A., & Muzaffar, H. (2023). Potential treatment of anthrax infection. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *3*, 576–588.

Askarizadeh, M., Esfandiari, N., Honarvar, B., Sajadian, S. A., & Azdarpour, A. (2023). Zero-order kinetics describes drug absorption where the rate is constant and independent of drug concentration. *ChemBioEng Reviews*, *10*(6), 1006–1049.

Barros, M. T., Paci, M., Tervonen, A., Passini, E., Koivumäki, J. T., Hyttinen, J., & Lenk, K. (2024). From multiscale biophysics to digital twins of tissues and organs: future opportunities for in-silico pharmacology. *IEEE Transactions on Molecular, Biological, and Multi-Scale Communications*.

Bicker, J., Alves, G., Falcão, A., & Fortuna, A. (2020). Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics. *British Journal of Pharmacology*, *177*(10), 2215–2239.

Contri, R. V, Gazzi, R. P., Pohlmann, A. R., Guterres, S. S., & Frank, L. A. (2022). Drug release from pharmaceutical nanocarriers. In *The ADME Encyclopedia: A Comprehensive Guide on Biopharmacy and Pharmacokinetics* (pp. 419–428). Springer.

Emmett, S. R., Hill, N., & Dajas-Bailador, F. (2019). *Clinical Pharmacology for Prescribing*. Oxford University Press.

Faisal, M., Iqbal, T., Usama, M., Ahmad, K., Khan, M. S., Waris, I., Raza, H., Ghafoor, R., Tahir, U. Bin, & Iftikhar, R. (n.d.). *Elucidating the Anthelmintic Efficacy and Phytochemical Profile of Citrullus colocynthis (Linnaeus) Schrader*.

Fatima, M., Iqbal, T., Shaheen, L., Salma, U., Siddique, R., Ali, R., Rehman, A. U., & Usman, S. (2023). Transmission dynamics of rabies virus. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *3*, 386–397.

Foster, D. M., & Vicini, P. (2022). Noncompartmental and compartmental approaches to pharmacokinetic data analysis. In *Atkinson's Principles of Clinical Pharmacology* (pp. 113–135). Elsevier.

Gharat, S. A., Momin, M. M., & Khan, T. (2024). Pharmacokinetic, Pharmacodynamic, Preclinical and Clinical Models for Evaluation of Nanoparticles. In *Pharmacokinetics and Pharmacodynamics of Novel Drug Delivery Systems: From Basic Concepts to Applications: A Machine-Generated Literature Overview* (pp. 81–178). Springer.

Gulnaz, R., Saqib, M., Saleem, M., Fatima, M., Iqbal, T., & Arif, Z. (2023). Outbreak of the ebola virus. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *3*, 359–373.

Heramvand, N. (2023). *Merits and Limits of Biological Systems Modeling Strategies*. Dissertation, Düsseldorf, Heinrich-Heine-Universität, 2022.

Humaira, H. A., Iqbal, T., Habib, I., & Aman, Z. (2023). Vaccine strategies for dengue fever. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *3*, 561–575.

Iqbal, M. U., Altaf, S., Naeem, M. A., Aufy, M., Alfuraydi, A. A., Iqbal, T., Hussein, A. M., Maksoud, M. A. A., & Malik, A. (2024). Amelioration of Organophosphate Poisoning Using Red Blood Cell Membrane-Cloaked Oil Nano-Sponge. *Journal of Biological Regulators and Homeostatic Agents*, 5753–5767. https://doi.org/10.23812/J.BIOL.REGUL.HOMEOST.AGENTS.20243808.462

Iqbal, T., Ahmad, A., Naveed, M. T., Ali, A., & Ahmad, M. (2023). Potential Role of Zoonoses in Bioterrorism. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *1*, 499–512.

Iqbal, T., & Altaf, S. (2024). *Nigella Sativa use for the Treatment of Cancer*. https://doi.org/10.26717/BJSTR.2024.55.008660

Iqbal, T., Altaf, S., Basit, I., Naeem, M. A., Akram, Q., Saeed, M. R., Hyder, S., & Salma, U. (2024). Hesperetin: A Potent Phytochemical Constituent for the Treatment of Rheumatoid Arthritis: Hesperetin for the Treatment of Rheumatoid Arthritis. *Pakistan BioMedical Journal*, 2–10.

Iqbal, T., Altaf, S., Fatima, M., Rasheed, R., Laraib, K., Azam, M., Karamat, M., Salma, U., & Usman, S. (2024). *A narrative review on effective use of medicinal plants for the treatment of parasitic foodborne diseases. Agrobiological Records 16: 79-92*.

Iqbal, T., Altaf, S., Salma, U., Fatima, M., Khan, M. N., Farooq, S., Abrar, M., Tasleem, M., & Afzal, A. (2024). *Cell membrane coated polymeric nanocarriers: a novel drug delivery approach for the targeted therapy of rheumatoid arthritis. Agrobiological Records 15: 91-102*.

Iqbal, T., Fatima, M., & Altaf, S. (n.d.). *Role of Platelet Membrane Coated Nanoparticles to Treat Rheumatoid Arthritis*.

Iqbal, T., Salma, U., Umair, M., Iqbal, H., Khalid, T., & Hyder, S. (2024). Utilizing Medicinal Plants for Disease Treatment in Aquaculture: An Approach to Improve Fish Health: Medicinal Plants in Aquaculture. *MARKHOR (The Journal of Zoology)*, 3–10.

Jebreili, S., & Goli, A. (2024). Optimization and computing using intelligent data-driven. *Optimization and Computing Using Intelligent Data-Driven Approaches for Decision-Making: Optimization Applications*, *90*.

Lamba, D., & Pesaresi, A. (2022). Kinetic modeling of time-dependent enzyme inhibition by pre-steady-state analysis of progress curves: The case study of the anti-alzheimer's drug galantamine. *International Journal of Molecular Sciences*, *23*(9), 5072.

Meesters, K., Balbas-Martinez, V., Allegaert, K., Downes, K. J., & Michelet, R. (2024). Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians. *Pediatric Drugs*, 1–15.

Mittal, A., Ghai, R., Srivastava, A., Ghosh, D. P., & Nagarajan, K. (2023). Pharmacokinetics and Pharmacodynamics: Fundamentals and Role (s) in Drug Discovery and Development. In *Recent Advances in Pharmaceutical Innovation and Research* (pp. 357–393). Springer.

Mushtaq, H., Zahid, H., Ahmad, D., Sattar, A., & Iqbal, T. (n.d.). *Efficacy of Homeopathic Therapy in Arthritis Treatment*.

Onita, T., Ishihara, N., & Yano, T. (2025). PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance. *Antibiotics*, *14*(1), 92.

Papachristos, A., Patel, J., Vasileiou, M., & Patrinos, G. P. (2023). Dose optimization in oncology drug development: the emerging role of pharmacogenomics, pharmacokinetics, and pharmacodynamics. *Cancers*, *15*(12), 3233.

Peters, S. A. (2021). *Physiologically based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry*. John Wiley & Sons.

Preijers, T., Muller, A. E., Abdulla, A., de Winter, B. C. M., Koch, B. C. P., & Sassen, S. D. T. (2024). Dose individualisation of antimicrobials from a pharmacometric standpoint: the current landscape. *Drugs*, *84*(10), 1167–1178.

Ramadan, Q., Fardous, R. S., Hazaymeh, R., Alshmmari, S., & Zourob, M. (2021). Pharmacokinetics-on-a-chip: in vitro microphysiological models for emulating of drugs ADME. *Advanced Biology*, *5*(9), 2100775.

Saleem, F., Atiq, A., Altaf, S., Habib, M., & Iqbal, T. (2023). Etiology, treatment and complications of dengue fever: a systematic analysis. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *3*, 551–560.

Saleem, M., Munir, R., Aslam, T., Altaf, S., & Aziz, A. (n.d.). *Mathematical Pharmacokinetics and Drug Delivery*.

Salma, U., Nawaz, H., Farooq, M., & Iqbal, T. (2023). Management, control and treatment of monkeypox disease. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *3*, 666–675.

Saqib, M., Iqbal, K. J., Khan, S., Gulnaz, R., Iqbal, T., Mankga, L. T., & Fatima, K. (2023). Immune boosters to combat zoonotic viral diseases. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *3*, 344–358.

Sharma, A., Verma, S., Bhatt, D. L., Connelly, K. A., Swiggum, E., Vaduganathan, M., Zieroth, S., & Butler, J. (2022). Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? *Basic to Translational Science*, *7*(5), 504–517.

Sharif, M. N., Hina, A., Gull, D., Tariq, M., Khaliq, H., Mahmood, W., Zakir, A., Ul Hassan, W., Altaf, S., & Sajjad, A. (2025). Eco-friendly biosynthesis of iron oxide nanoparticles for targeted cancer imaging and therapy. *Journal of Medical & Health Sciences Review*, 2(2), 4407-4418.

Terranova, N., Renard, D., Shahin, M. H., Menon, S., Cao, Y., Hop, C. E. C. A., Hayes, S., Madrasi, K., Stodtmann, S., & Tensfeldt, T. (2024). Artificial intelligence for quantitative modeling in drug discovery and development: an innovation and quality consortium perspective on use cases and best practices. *Clinical Pharmacology & Therapeutics*, *115*(4), 658–672.

Umair, M., Altaf, S., Muzaffar, H., Iftikhar, A., Ali, A., Batool, N., Iqbal, T., & Saif-ur-Rehman, B. S. R. (2022). Green nanotechnology mediated silver and iron oxide nanoparticles: Potential antimicrobials. *Agrobiol Rec*, *10*, 35–41.

Veiga-Matos, J., Remião, F., & Motales, A. (2020). Pharmacokinetics and toxicokinetics roles of membrane transporters at kidney level. *Journal of Pharmacy & Pharmaceutical Sciences*, *23*, 333–356.

Vlot, A. H. C., Aniceto, N., Menden, M. P., Ulrich-Merzenich, G., & Bender, A. (2019). Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls. *Drug Discovery Today*, *24*(12), 2286–2298.

Wadhwa, R. R., & Cascella, M. (2020). *Steady state concentration*.

Wang, D., Hensman, J., Kutkaite, G., Toh, T. S., Galhoz, A., William, G. S. T. L. H. Y. W. S. M. B. S. M. T. B. A. R. L. L. E. H. J. T. C. B., Dry, J. R., Saez-Rodriguez, J., Garnett, M. J., & Menden, M. P. (2020). A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates. *Elife*, *9*, e60352.

Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023). The blood–brain barrier: structure, regulation, and drug delivery. *Signal Transduction and Targeted Therapy*, *8*(1), 217.

Xiao, J. (2022). *Pharmacometric Modeling and Simulation in Special Populations*.

Zhao, F., Wu, Y., Hu, M., Chang, C.-W., Liu, R., Qiu, R., & Yang, X. (2024). Current Progress of Digital Twin Construction Using Medical Imaging. *ArXiv Preprint ArXiv:2411.08173*.